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The interferon-regulated transcription factor and tumor sup-
pressor protein IRF-1 is predicted to be largely disordered out-
side of the DNA-binding domain. One of the advantages of
intrinsically disordered protein domains is thought to be their
ability to take part in multiple, specific but low affinity protein
interactions; however, relatively few IRF-1-interacting proteins
have been described. The recent identification of a functional
binding interface for the E3-ubiquitin ligase CHIP within the
major disordered domain of IRF-1 led us to ask whether this
region might be employed more widely by regulators of IRF-1
function. Here we describe the use of peptide aptamer-based
affinity chromatography coupled with mass spectrometry to
define a multiprotein binding interface on IRF-1 (Mf2 domain;
amino acids 106–140) and to identify Mf2-binding proteins
from A375 cells. Based on their function as known transcrip-
tional regulators, a selection of the Mf2 domain-binding pro-
teins (NPM1, TRIM28, and YB-1) have been validated using in
vitro and cell-based assays. Interestingly, although NPM1,
TRIM28, and YB-1 all bind to theMf2 domain, they have differ-
ing amino acid specificities, demonstrating the degree of com-
binatorial diversity and specificity available through linear
interaction motifs.
Transcription factors and proteins involved in cell signaling
pathways appear to have a disproportionately high number of
intrinsically disordered (ID)2 domains, suggesting that such
regions are of particular importance in their regulation and
mode of action (1–5). Current thinking on the role of ID
domains suggests that these flexible structures may confer
advantages in protein-protein and protein-ligand interactions
when compared with more rigid globular domains. For exam-
ple, it has been proposed that greater plasticity could permit the
binding of structurally diversemolecules to the same domain or
that they might encourage the kind of highly specific but low
affinity interactions that are advantageous in cell signaling. It
has also been suggested that ID domains contain a high propor-
tion of the proteome’s linear interactionmotifs (6, 7). These are
protein interaction motifs that may contain 10 or fewer resi-
dues. In addition, ID domains appear to facilitate fine control
and regulation by post-translational modification (6, 7).
The interferon-regulated transcription factor IRF-1 (inter-
feron regulatory factor-1) is involved in a variety of physiolog-
ical processes, including the antiviral response and tumor sup-
pression (8, 9). Specifically, IRF-1 regulates the expression of a
cohort of genes involved in immunity and/or negative cell
growth, either directly, through binding to interferon respon-
sive elements in target genes (10, 11), or indirectly, through its
ability to interact with other transcription factors and coactiva-
tors (12). For example, IRF-1 binds to an interferon-responsive
element in the promoter of target genes like ISG20 and Trail
(13, 14). Alternatively, IRF-1 interacts with the transcriptional
coactivator p300 throughmotifs within the transactivation and
enhancer domains; this interaction promotes p300-dependent
acetylation and activation of p53, leading to an increase in
expression of the p53 target gene p21WAF1 (12). Interestingly,
the effect of full-length IRF-1 on p300-mediated acetylation of
p53 can be recapitulated in trans using peptides containing the
p300 binding motifs from IRF-1 (12, 15). This finding suggests
that the ability of IRF-1 to interact with other transcriptional
regulators is pivotal to its physiological function (12, 15, 16).
Despite the fact that existing evidence suggests that IRF-1
function is highly regulated by post-translational mechanisms
(17–20) and that it represents a network hub for radiosensitiv-
ity and various human diseases (21–23), the identification of
regulatory factors that function through protein-protein inter-
actions with IRF-1 is limited (24, 25). Here we report the appli-
cation of affinity chromatography using IRF-1-based peptide
aptamers to identify proteins that interact with the Mf2 inter-
face fromwithin amajor IDdomain in the central portion of the
IRF-1 protein. This has led us to characterize a multiprotein
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binding interface employed by IRF-1 regulatory proteins, which
interact with discrete but overlapping motifs.
MATERIALS ANDMETHODS
Reagents—Antibodies were used at 1 g/ml or as recom-
mended by the supplier and were anti-IRF-1 (BD Biosciences),
anti-YB-1 and anti-GAPDH (Abcam), anti-FLAG and anti-
GST (Sigma), anti-NPM (Zymed Laboratories Inc.), anti-His
(Novagen), anti-Myc (Cancer Research UK), and anti-KAP-1
(Bethyl Laboratories). Secondary antibodies were purchased
from Dako Cytomation. Peptide libraries were purchased from
Chiron Mimotopes and were synthesized with a biotin tag at
the N terminus and an SGSG spacer. Bulk biotin-SGSG-linked
peptides were from Genscript and were 93% pure (purifica-
tion and quality control are described in supplemental Method
S1). GST- and FLAG-TRIM28 (KAP-1) were kind gifts from A.
Ivanov (26). His-NPMwas from F. Carrier (University ofMary-
land) (27).
Cell Culture, Lysis, and Immunoblots—A375 cells cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen), supple-
mented with 10% (v/v) fetal bovine serum (Autogen Bioclear)
and 1% (v/v) penicillin/streptomycin mix (Invitrogen), were
maintained in 10% CO2 at 37 °C. H1299 cells were cultured in
RPMI 1640 (Invitrogen) supplemented with serum and antibi-
otics (as above) and maintained in 5% CO2 at 37 °C. For tran-
sient transfection, cells were seeded 24 h before transfection,
and DNA (as indicated in the figure legends) was transfected
into the cells using Attractene (Qiagen) as described in the
manufacturer’s handbook. Cell lysis and immunoblotting were
as described previously (28).
Peptide Affinity Chromatography—A library of 22 peptide
aptamer affinity columns were generated using Mobicol col-
umn jackets (MoBiTec) by incubating streptavidin-agarose
(50-l packed volume; binding capacity 24.5g biotin/ml) with
biotin-peptide (11.5mM; this was sufficient to saturate all bind-
ing sites on the column) for 1 h at room temperature, and pep-
tide-binding proteins from A375 lysate were isolated as
described previously (28). For one-dimensional electrophore-
sis, sampleswere run out on a 4–12%NuPAGEgel (Invitrogen),
and stained with Colloidal Blue (Invitrogen) according to the
manufacturer’s instructions. For the two-dimensional gel
method see supplemental Method S2. Protein bands were
excised from the gel using a clean, sharp scalpel and digested
with trypsin as described below. Alternately, the NuPAGE gels
were transferred to nitrocellulose and immunoblotted as
required.
Enzymatic In-gel Digestion—Stained protein bands were
excised from the gel, washed with deionized water, cut into
small pieces, and destained with freshly prepared 200 mM
NH4HCO3 (pH 7.8) in 40% acetonitrile for 20 min at 30 °C,
followed by equilibration in 50 mM NH4HCO3 (pH 7.8) in 5%
acetonitrile for 30 min at 30 °C. The supernatant was removed,
and the gel was dried in a SpeedVac concentrator. Next, the
samples were reduced by the addition of 10 mM DTT for 1 h at
60 °C, followed by alkylation with 20 mM iodoacetamide in the
dark for 45 min at room temperature. The supernatant was
removed, and the gel pieces were washed three times with
equilibration buffer and acetonitrile. After vacuum drying, the
gel pieceswere rehydrated in a cleavage buffer containing equil-
ibration buffer and trypsin (40 ng/l; Promega; cleaves at the
carboxyl side of Lys or Arg except when either is followed by
Pro) for 20min at 4 °C. Finally, 15–60l of equilibration buffer
was added to cover the gel. The sampleswere incubated for 18 h
at 37 °C. The digestion was stopped by the addition of 5% TFA
in acetonitrile, and the aliquot of the resulting peptide mixture
was desalted using a GELoader microcolumn (Eppendorf)
packed with Poros Oligo R3 material (29). The purified and
concentrated peptides were eluted from the microcolumn in
several droplets directly onto MALDI plates using 1 l of
-cyano-4-hydroxycinnamic acid matrix solution (5 mg/ml in
50% acetonitrile, 0.1% TFA).
MALDI Mass Spectrometry—Mass spectra were measured
on an Ultraflex III MALDI-TOF/TOF instrument (Bruker Dal-
tonics) equipped with a smartbeamTM solid state laser and
LIFTTM technology for MS/MS analysis. Peptide mass finger-
printing spectra were acquired in the positive reflectron mode,
in the mass range of 700–4000 Da, and calibrated internally
using the monoisotopic [M H] ions of trypsin autoproteo-
lytic fragments (842.5 and 2211.1 Da).
For peptide mass fingerprinting data base searching, peak
lists in XLM data format were created using flexAnalysis soft-
ware (version 3.0, BrukerDaltonics) with the SNAPpeak detec-
tion algorithm. No smoothing was applied, and the maximal
number of assigned peaks was set to 50. After peak labeling, all
known contaminant signals were removed. The peak lists were
searched using an in-house MASCOT search engine against a
SwissProt 2010_07 database subset of human proteins (518,415
entries) with the following search settings: peptide tolerance of
20 ppm, missed cleavage site value set to 2, variable carbam-
idomethylation of cysteine, oxidation on methionine, and pro-
tein N-terminal acetylation. No restrictions on protein molec-
ular weight and pI value were applied. Proteins with molecular
weight search scores over the threshold 56 calculated for the
used settings were considered as identified. If the score was
lower or only slightly higher than the threshold value, the iden-
tity of the protein candidate was confirmed byMS/MS analysis.
In addition to the above-mentioned MASCOT settings, frag-
ment mass tolerance of 0.6 Da and instrument type MALDI-
TOF/TOF was applied for searching of MS/MS spectra.
Affinity Chromatography Using GST-IRF-1—GST-IRF-1,
GST-AGR2, and GST alone were expressed in BL21-AI (Invit-
rogen) cells and purified using glutathione-Sepharose (GE
Healthcare) according to the manufacturer’s instructions.
However, the protein was not eluted; instead, binding assays
were carried out as described previously (28).
Protein InteractionAssay—GST-IRF-1 orGST alone (250 ng)
were coated onto a white 96-well plate in 0.1 M NaHCO3 buffer
(pH 8.6) overnight at 4 °C. Non-reactive sites were blocked
using PBS containing 3% (w/v) BSA. His-NPM (0–64 ng) was
added in Reaction Buffer (25 mMHepes, pH 7.5, 50 mM KCl, 10
mM MgCl2, 5% (v/v) glycerol, 0.1% (v/v) Tween 20, 2 mg/ml
BSA) for 1 h at room temperature. After washing extensively
with PBS supplemented with 0.1% (v/v) Tween 20 (PBST)
between steps, binding was measured using anti-His and HRP-
tagged anti-mouse antibodies, and luminescence was quanti-
fied using a luminometer (Labsystems, Fluoroskan Ascent FL).
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Alternatively, His-NPM (100 ng) (or TRIM28; see below) was
coated onto a microtiter plate as described above. After block-
ing, the wells were incubated with a titration of GST alone,
GST-IRF-1 WT, or GST-IRF-1 106–140 (0–25 ng) in Reac-
tion Buffer, and bindingwas detected using anti-GST andHRP-
tagged anti-mouse antibodies, with extensive washing in
between as above. Luminescence was quantified using a lumi-
nometer (Labsystems, Fluoroskan Ascent FL).
For TRIM28-IRF-1 protein interaction assays, untagged
IRF-1, expressed and purified using the PUREsystem Classic
II (Post Genome Institute, Tokyo, Japan), was coated onto a
white 96-well plate as above. TRIM28 (0–128 ng), purified as
GST-TRIM28 using glutathione-Sepharose and subsequently
cleaved on the columnusing thrombin, was added in themobile
phase. It should be noted that TRIM28 itself contains a throm-
bin cleavage site and was therefore processed into two frag-
ments during cleavage, both of which were present in the
mobile phase. Binding was detected using anti-TRIM28 and
HRP-tagged anti-rabbit antibodies.
For peptide-protein interaction assays (direct peptide bind-
ing assay), streptavidin (1g/well) was coated onto amicrotiter
plate overnight at 37 °C and then incubated with biotin-tagged
peptide to saturate the wells (60 pmol). Wells were washed
and blocked as above and incubated with a titration of His-
NPM (0–250 ng) in Reaction Buffer as above. Binding was
detected using anti-His and HRP-tagged anti-mouse antibod-
ies, and luminescence was quantified using a luminometer as
described above.
Peptide Competition Assay—GST-IRF-1 (100 ng) was coated
onto a white 96-well plate in 0.1 M NaHCO3 buffer (pH 8.6)
overnight at 4 °C. Non-reactive sites were blocked using PBS
containing 3% BSA. Peptide (0–1.25 M or 0–5 M as indi-
cated) or an equal amount of carrier alone was added to His-
NPM (100 ng) (or TRIM28) in Reaction Buffer (as above) and
incubated for 15 min at room temperature. The mix was then
added to the 96-well plate coated with GST-IRF-1 and incu-
bated for a further 1 h at room temperature. Following exten-
sive washing in PBST, binding was detected using anti-His and
HRP-tagged anti-mouse antibodies (or anti-TRIM28 and anti-
rabbit antibodies), and luminescence was measured as above.
Immunoprecipitation—A375 cells were harvested and lysed
with 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1% Nonidet P-40,
0.15 M NaCl, 10% glycerol, 0.1 mM sodium molybdate, 1 mM
pefabloc, 1 mM sodium orthovanadate, and 1 mM DTT. The
lysate (4 mg of total protein) was incubated (150 min at 4 °C)
with anti-IRF-1 antibody (1 g/reaction) chemically cross-
linked to protein G-Sepharose using DMP (30). In the bead
control, lysate was incubatedwith untreated proteinG-Sephar-
ose. The beads were washed two times inWash Buffer contain-
ing 0.5 M NaCl followed by two washes inWash Buffer only (25
mMHEPES, pH 7.5, 1 mM EDTA, 0.1%Nonidet P-40, 10% glyc-
erol, 0.2 mg/ml benzamidine, 10 mM -glycerophosphate, 0.5
mM sodium orthovanadate, and 50 mM NaF). Bound proteins
were analyzed following the addition of sample buffer using
10% SDS-PAGE/immunoblot.
Complex Pull-downs—OneSTREP-tagged IRF-1 (or empty
vector) alone or plus FLAG-TRIM28was transfected into A375
cells (2 100-mmplates/IP condition, transfected according to
the manufacturer’s instructions). Post-transfection (24 h), cells
were harvested and lysed in Triton Lysis Buffer (50mMHEPES,
pH 7.5, 0.2% (v/v) Triton X-100, 150 mM NaCl, 10 mM NaF, 2
mM DTT, 0.1 mM EDTA, protease inhibitor mix). Following
this, tagged complexes were isolated using either Streptactin
macroprep (IBA), or FLAG-agarose beads (Sigma) according
to the manufacturer’s instructions. Eluates were analyzed by
SDS-PAGE/immunoblot using anti-IRF-1, anti-YB-1, and
anti-FLAG antibodies. In the case of OneStrep-IRF-1NPM
complex formation, A375 cells were transiently transfected
with 0.5 g of OneStrep-IRF-1 or empty vector and scraped
into ice-cold PBS 24 h post-transfection. Cells were lysed as
described above (see “Immunoprecipitation”), following
which OneStrep-tagged complexes were isolated using Strep-
tactin macroprep essentially according to the manufacturer’s
instructions except using the wash conditions described under
“Immunoprecipitation.”
Dual Luciferase Reporter Assay—Luciferase reporter assays
were carried out in H1299 cells as described previously (31)
using 120 ng of either p125-luc IFN (which contains the
human IFN- promoter region125 to19) or a control plas-
mid p55-luc IFN (which lacks the interferon-stimulated
response element or ISRE; promoter region 55 to 19),
TLR3-Luc (hTLR3–588) or hTLR3IRF (a mutant lacking the
ISRE), TRAIL (pTRL3 or a mutant minus the ISRE/IRFE,
pTRL3m6), and IL-7 (609-Luc or a mutant 609-mtIRF-E-
Luc, which is missing the ISRE) (28, 31). Reporter activity was
determined 24 h post-transfection using luciferase lumines-
cence as a read-out.
RESULTS
The Use of Peptide Aptamer Affinity Chromatography—Us-
ing data generated by the DISOPRED2 Disorder Prediction
Server (32), we estimate that30% of IRF-1 structure is intrin-
sically disordered (Fig. 1, A and B), identifying IRF-1 as a mem-
ber of a class of proteins that are described as highly unstruc-
tured (3, 7).We recently discovered that the E3-ubiquitin ligase
CHIP binds to a site (amino acids 106–140) within the major
disordered domain of IRF-1 (Fig. 1C), facilitating ubiquitina-
tion of IRF-1 under specific stress conditions (33). Because dis-
ordered domains appear to favor multiple protein interactions,
we speculated that the major disordered domain in IRF-1 may
bind to other components of the IRF-1 regulatory network.
Rather than selecting just theCHIP-binding domain for anal-
ysis (Fig. 1) (33), we decided to take a less biased approach by
determining the binding profile for aptamers that spanned the
entire sequence of IRF-1 (Fig. 2A). Affinity columns bearing
overlapping IRF-1-based peptides were generated and used to
screen for interacting proteins from A375 cell lysates (supple-
mentary Fig. S3A). When total bound protein was analyzed
(Fig. 2B), it was striking that only a limited number of columns
(e.g. columns 8, 9, 12, and 21) gave a diversity of interacting
factors relative to background (Fig. 2B) and to a column bearing
a biotinylated control peptide (supplemental Fig. S3B). In addi-
tion, the binding proteins did not necessarily correspond to
proteins that were highly represented in the crude lysate (sup-
plemental Fig. S3B). Consistent with the hypothesis that the
major unstructured domain of IRF-1 (Leu112–Val188; Fig. 1B) is
Multiprotein Binding Interface in IRF-1
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likely to be a hot spot for regulatory interactions and post-
translational events, tens of protein bandswere eluted from two
overlapping peptides from themajor IDdomain (peptides 8 and
9; Fig. 2, A and B). These two peptides also contain the CHIP-
docking site (33), suggesting that they may form amultiprotein
binding interface on IRF-1. We have named this the Mf2 (mul-
tifunctional 2) domain (Fig. 1C).
Preliminary analyses, where a range of protein bands from
theMf2 columns were selected, demonstrated that the amount
of individual proteins was sufficient for identification by mass
spectrometry. A comprehensive analysis of the proteins bound
to columns 8 and 9was therefore carried out (supplemental Fig.
S3B) based on the identification of peptide profiles from the
mass spectrum of digested proteins (peptide mass fingerprint-
ing) and confirmation of protein identity by fragmentation of
one or more selected peptides from the MS spectrum in the
case of poor peptide mass fingerprinting identification. We
used this approach for identification of samples from both one-
and two-dimensional gels (supplemental Fig. S3C and Method
S2), and the measurement was performed by MALDI TOF/
TOF mass spectrometry (supplemental Table T1). The identi-
fied proteins were then analyzed using the Database for Anno-
tation, Visualization, and Integrated Discovery (DAVID,
version 6.7) (34,35) to group them into functional biological
categories (Fig. 2C).
Because we are particularly interested in the identification of
IRF-1-interacting proteins that may regulate its transactivation
or tumor suppressor activity, we focused on proteins that fell
into the categories of transcriptional regulators and proto-on-
cogenes (Fig. 2D). From this list, we picked three proteins that
were of particular interest with respect to potential post-trans-
lational regulation of IRF-1 (i.e. known transcriptional regula-
tors that also had a link to cancer) (NPM, YB-1, and TRIM28)
and carried out a more detailed validation. Interestingly,
although a number of novel Mf2 domain interactions were
identified, we did not identify CHIP by this method. This could
be due to the low levels of CHIP expressed in A375 cells, or it
may reflect the fact that IRF-1CHIP complexes form preferen-
tially in cells exposed to heat or heavy metal stress (33). Thus,
CHIP binding to the Mf2 domain of IRF-1 in unstressed cells
may be negatively regulated by otherCHIP-interacting proteins
or by post-translational modification.
Validation of NPM Binding to IRF-1—One of the Mf2-inter-
acting proteins identified above, NPM (supplemental Table
T1), is a nuclear phosphoprotein and chaperone that has been
implicated in the regulation of a number of transcription fac-
tors with oncogene or tumor suppressor activity and can itself
act as an oncogene (36–40). Although previously identified as a
potential regulator of IRF-1 (25), the link between IRF-1 and
NPM has not been characterized at the molecular level. To
address this, we first validated binding of NPM to the Mf2
domain peptides using immunoblot analysis (Fig. 3A). NPM
bound primarily to peptide 9, although in line with the MS
analysis (supplemental TableT1), weak binding ofNPMtopep-
tide 8 was also detected on longer exposures (data not shown).
Thus, NPM predominantly binds to peptide 9 of the Mf2
domain, forming a stable isolatable complex.
FIGURE 1. TheMf2 region of IRF-1 lacks a defined structure and is highly
disordered. A, analysis of the IRF-1 protein sequence for disorder probability
usingDISOPRED2 (available on theWorldWideWeb) (35)with a false positive
rate of 5%. The “filter” curve represents the output fromDISOPRED2, and the
“output” curve shows the output from a linear SVM classifier (DISOPREDsvm).
The output from DISOPREDsvm is included to indicate shorter, low confi-
dence predictions of disorder. B, amino acid sequence (AA) of IRF-1 with pre-
dicted (pred) disordered residues (*) obtained by DISOPRED2 analysis shown.
C, schematic showing the location of the highly disordered Mf2 region in
relation to other defined domainswithin the IRF-1 protein.Mf1 is amultifunc-
tional regulatory domain (28).
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FIGURE2.Developmentof abiochemical screen to identifynovel IRF-1-bindingproteins.A, overlappingpeptides (20 aminoacids longwith anN-terminal
biotin tag and SGSG spacer and 5-amino acid overlap) spanning the entire length of the IRF-1 protein that were used to generate peptide aptamer affinity
columns. B, eluates from the peptide aptamer affinity chromatography columns were analyzed on 4–12% gradient gels, and protein bands were detected
using colloidal blue stain. C, pie chart showing the IRF-1-binding proteins identified by mass spectrometry that were analyzed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID) (34, 35) and classified by Uniprot keyword into functional biological categories. The table shown
lists the number of identified proteins in each functional category; the percentage with respect to the total number of identified proteins (%); the p value,
indicating significance; and the enrichment score, showing the enrichment of each category in the IRF-1 column eluates when compared with its occurrence
in the human proteome. D, table expanding on the output from DAVID showing proteins classified as transcriptional regulators and proto-oncogenes.
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In order to establish if NPM could bind to full-length IRF-1,
a column ofGST-IRF-1 immobilized on glutathione-Sepharose
beads was loaded with A375 cell lysate and washed extensively.
Bound proteins were analyzed by SDS-PAGE/immunoblot fol-
lowing incubation of the beads with SDS sample buffer. NPM
bound to the IRF-1 containing column but not to GST alone or
GST-AGR2 control columns (Fig. 3B). The interaction between
IRF-1 and NPM was demonstrated to be direct by carrying out
a protein interaction assay using purified components. GST or
GST-IRF-1 was coated onto a microtiter well and incubated
with His-NPM, expressed and purified from E. coli, which was
in the mobile phase. This showed that IRF-1, but not GST,
could interact directly with NPM in the absence of other cellu-
lar factors (Fig. 3C). To determine whether the binding of NPM
to full-length IRF-1 was through theMf2 domain, the following
approaches were taken. First, a mutant IRF-1 protein was used
in which the Mf2 domain (amino acids 106–140; GST-IRF-1
106–140) had been deleted (33). Binding of NPM to the Mf2
domain deletion mutant was significantly impaired when com-
pared with binding to wild-type IRF-1 (Fig. 3D). Second, the
ability of peptide 9 to diminish NPM binding by competing
with full-length IRF-1 was measured. When NPM and IRF-1
levels were kept constant and peptide 9 was titrated into the
assay, it competed with full-length IRF-1 for binding to NPM
(Fig. 3E), whereas, consistent with the weak binding detected in
Fig. 3A, peptide 8 had no significant effect on NPM binding
when compared with a DMSO control. The data presented in
this section suggest that the region represented by peptide 9
(amino acids 121–140) is the major interface for NPM on
IRF-1.
FIGURE 3. NPM binds to the Mf2 region of IRF-1. A, eluates from the peptide aptamer affinity chromatography columns (see supplemental Fig. S3A) were
analyzed on 4–12%gradient gels. NPMbindingwas determinedby immunoblot developedusing anti-NPM. B, immunoblot showing the binding of NPM from
A375 lysates to recombinant GST, GST-IRF-1, and GST-AGR2 immobilized on glutathione-Sepharose. The immunoblot was developed using anti-NPM. The
lysate was analyzed on the same gel, but the lanes were not contiguous and the data are representative of at least two independent experiments. C, GST or
GST-IRF-1 was coated onto a microtiter plate and incubated with a titration (0–64 ng) of His-NPM. Binding was detected using an anti-His antibody and
enhanced chemiluminescence. The amount of protein (ng) against binding, expressed as relative light units (RLU), is shown. The results are representative of
two separate experiments. D, recombinant His-NPMwas coated on a microtiter plate and incubated with a titration (0–25 ng) of GST alone, GST-IRF-1 WT, or
GST-IRF-1 106–140. Binding was detected as above except using anti-GST. E, GST-IRF-1 was coated onto a microtiter plate, following which a fixed amount
ofHis-NPMpreincubatedwith a titration (0–1.25M) of peptide 8, peptide 9, or theDMSOcarrier, was added to theplate. Bindingwasdetected as inC. Peptide
concentration against binding, expressed as relative light units, is shown. The data are representative of two independent experiments.
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NPM Binding to a Short Linear Motif—Recent studies have
suggested that ID domains frequently house linear interaction
motifs that can be composed of 10 or fewer amino acids. To
determine whether theMf2 domain contained a linear interac-
tion motif that bound to NPM, we defined residues critical for
binding using a library of peptide 9 derivatives in which each
amino acid had been sequentially mutated to Ala (Fig. 4A). The
librarywas used to generate individual affinity chromatography
columns, and the ability ofNPM fromA375 cell extracts to bind
the mutant peptides was determined. This showed that a core
FIGURE 4.NPM binds specifically to a basic linear interactionmotif within the Mf2 region of IRF-1. A, eluates from peptide aptamer affinity chromatog-
raphy columns based on peptide 9, where each amino acid had been sequentially mutated to alanine, were analyzed on 4–12% gradient gels, and NPMwas
detected by immunoblot using anti-NPM. B, affinity columnswere generated using the indicated peptides. C1 (IRF-1 peptide 4) and C2 (IRF-1 peptide 21)were
used as controls for nonspecific binding, and NPM binding was analyzed as in A. C, a fixed amount of the indicated peptides (or a carrier alone control; DMSO)
was immobilized on a streptavidin-coated microtiter plate and incubated with a titration (0–250 ng) of His-NPM. Binding was detected using an anti-His
antibody and enhanced chemiluminescence. The amount of protein (ng) against binding, expressed as relative light units (RLU) is shown.
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motif comprising Lys134–Ser139 (KAKRKS) of IRF-1 contained
residues that were essential for stableNPMbinding, withmuta-
tion of Arg137 being sufficient to essentially abolish the interac-
tion. It should be noted that someother residues, such as Lys132,
also appeared to make a contribution to binding, although they
were not as critical as the coremotif. Based on the results of the
Ala scan, two shorter peptides 131AKSKAKRKSC140 and
133SKAKRKSC140 were generated, both of which contained the
core KAKRKS residues and one of which also contained Lys132.
When asked to bind NPM from cell lysates, whereas the
131AKSKAKRKSC140 peptide retained capacity similar to that
of the WT peptide, the shorter 133SKAKRKSC140 peptide
showed reduced binding, suggesting that it had lost some of its
affinity for NPM (Fig. 4B). However, 133SKAKRKSC140 was as
efficient as theWT and 131AKSKAKRKSC140 peptides in bind-
ing to recombinant NPM (Fig. 4C). This suggests that either
Lys132 is more important for binding to endogenous NPM than
the recombinant protein or that the shorter peptide loses some
specificity and can therefore bind to a greater range of cellular
proteins, some of which would then compete with NPM for
binding. However, the fact that the 133SKAKRKSC140 peptide
retains significant activity for NPM binding suggests that the
core residues are both required and sufficient for the
interaction.
YB-1 and TRIM28 Bind to the ID Region of IRF-1—Having
validated NPM, a previously identified regulator of IRF-1 (25),
as a direct binding partner that interacts with a short linear
motif from the Mf2 domain of IRF-1, we moved on to look at
two potentially novel IRF-1-interacting factors. The two pro-
teins YB-1 and TRIM28 (also known as KAP1) were chosen
from the list of Mf2 binding proteins identified by MS analysis
(supplemental Table T1) on the basis that both of these pro-
teins are associated with the regulation of gene transcription
(41–43). First, we screened the IRF-1 peptide series for binding
to YB-1, a Y-box protein that is overexpressed in various cancer
types and has been reported to regulate both transcription and
translation. We found that, unlike NPM, which bound prefer-
entially to peptide 9 of theMf2 domain, cellular YB-1 interacted
equally well with both peptides 8 and 9 (Fig. 5A). This suggests
that although both YB-1 andNPMcan bind to theMf2 domain,
there is a difference in the exact interface they employ for bind-
ing. The specificity of YB-1 binding was demonstrated using a
series of peptides based on peptide 9, where residues that over-
lapped (KERKS) with the second YB-1-interacting aptamer,
peptide 8, were sequentially mutated to Ala. This showed that
although substitution of the Ser andGlu residues had no impact
on binding, the binding was specific because loss of a single
basic amino acidwas sufficient to significantly reduce the inter-
action (Fig. 5B) despite the fact that the net charge of the ala-
nine mutant peptides was still highly basic. In order to verify
that YB-1 could bind to theMf2 domain when in the context of
full-length IRF-1, binding of YB-1 to GST-IRF-1 immobilized
on glutathione-Sepharose was assessed. Fig. 5C shows that
whenA375 cell lysate was passed down theGST-IRF-1 column,
YB-1 bound specifically to IRF-1 because it was not present in
the eluate from either a GST alone column or a control column
containing GST-AGR2. Thus, endogenous cellular YB-1 can
bind to full-length immobilized IRF-1 protein.
We moved on to assess the possible interaction of TRIM28
with IRF-1. TRIM28 is a transcriptional corepressor that nor-
mally functions in concert with other repressors to regulate
gene expression (44, 45) and that has recently been associated
with metastasis of primary breast cancers (46). When we char-
acterized the interaction of endogenous cellular TRIM28 with
the IRF-1 peptide aptamer series, it boundpreferentially to pep-
tide 8 fromwithin theMf2 region, althoughweaker but consist-
ent binding to peptide 9 and to a couple of other N-terminal
domain peptides was also detected, suggesting that it forms a
complex interface with IRF-1 (Fig. 5D). This hypothesis was
supported by the fact that cellular TRIM28 could bind recom-
binant GST-IRF-1 immobilized on glutathione-Sepharose with
relatively high affinity to form a stable isolatable complex (Fig.
5E). To verify that the interaction between TRIM28 and IRF-1
was direct and that it did not require the presence of other
cellular proteins, we used purified proteins and demonstrated
binding of TRIM28 to IRF-1 when it was immobilized on a
microtiter plate, after cleaving off the GST tag (Fig. 5F).
Although data presented in Fig. 5D suggested that the interface
between IRF-1 and TRIM28 may be complex, the Mf2 domain
is shown to be integral to the interaction because peptide 8 can
compete very effectively with full-length IRF-1 for binding to
TRIM28 when compared with a control peptide or with the
peptide carrier (Fig. 5G; DMSO). Additionally, deletion of the
Mf2 domain from IRF-1 reduces TRIM28 binding to back-
ground levels (Fig. 5H), suggesting that the Mf2 domain con-
tains the primary binding interface for TRIM28 on IRF-1.
Cellular IRF-1 Complexes—Finally, we carried out protein
complex capture and immunoprecipitation assays in order to
establish whether any of the binding proteins characterized
above could be isolated in IRF-1 complexes from cells. First, we
determined the ability of OneStrep-tagged IRF-1 to interact
with endogenousNPMandYB-1 following capture of the IRF-1
FIGURE 5. YB-1 and TRIM28 bind to the highly disorderedMf2 region of IRF-1. A, eluates from the peptide aptamer affinity chromatography columns (see
supplemental Fig. S3A) were analyzed on 4–12% gradient gels. YB-1 binding was determined by immunoblot developed using anti-YB-1. B, affinity columns
weregeneratedusingpeptidesbasedonpeptide 9,where the residues that overlapwithpeptide 8 (KERKS)were sequentiallymutated toAla. YB-1bindingwas
analyzed as in A. C, immunoblot showing the binding of YB-1 from A375 lysate to recombinant GST, GST-IRF-1, and GST-AGR2 immobilized on glutathione-
Sepharose. The immunoblot was developed using anti-YB-1 polyclonal antibody. The data are representative of at least two independent experiments. D, as
in A except that TRIM28 bindingwas determined by immunoblot developed using anti-TRIM28. E, as in C, GST, GST-IRF-1, and GST-AGR2were immobilized on
glutathione-Sepharose, followingwhichA375 lysatewas incubatedwith the immobilizedproteins for 1h.After extensivewashing, boundproteinswereeluted
using sample buffer and analyzedby SDS-PAGE/immunoblot using anti-TRIM28. F, a fixed amount of untagged IRF-1 synthesizedusing the PUREsystemclassic
II protein synthesis kit was coated onto a microtiter plate and incubated with a titration (0–128 ng) of recombinant TRIM28. Binding was detected using
anti-TRIM28 and enhanced chemiluminescence. The amount of protein (ng) against binding, expressed as relative light units (RLU) is shown.G, GST-IRF-1 was
coated onto amicrotiter plate, following which a fixed amount of recombinant TRIM28 preincubated with a titration (0–5M) of peptide 8, a control peptide
(IRF-1 peptide 4), or the DMSO carrier was added to the plate. Binding was detected as in F. Peptide concentration against binding, expressed as relative light
units, is shown. H, recombinant TRIM28 was coated on a microtiter plate and incubated with a titration (0–25 ng) of GST alone, GST-IRF-1 WT, or GST-IRF-1
106–140. Binding was detected and expressed as in F except using anti-GST.
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complexes using Streptactin beads (Fig. 6A). Both endogenous
NPM and YB-1 were found in the OneStrep-IRF-1 pull-down
and not in the OneStrep control, suggesting that IRF-1NPM
and IRF-1YB-1 complex formation occurs in A375 cells (Fig.
6A) (for NPM, top, compare lanes 3 and 4; for YB-1, bottom,
compare lanes 6 and 7). For the IRF-1-TRIM28 interaction,
OneStrep-IRF-1 was co-transfected with FLAG-tagged
TRIM28. TRIM28 was then immunoprecipitated using an
anti-FLAG monoclonal antibody. Under these conditions,
IRF-1 co-precipitates with the TRIM28 immunocomplex
(Fig. 6B, compare lane 8 with lane 6). The results of the
experiments described in this section suggest that IRF-1 can
be found in cellular complexes with all three of the Mf2-
binding proteins investigated.
We next determined whether endogenous IRF-1 complexes
contained any of theMf2-binding proteins. Because IRF-1 runs
close to the antibody heavy chain on SDS-PAGE, we avoided
themajority of heavy chain contamination by first cross-linking
the IRF-1mAb to proteinGbeads. The IRF-1mAb cross-linked
beads were incubatedwith A375 cell lysate, and bound proteins
were analyzed by immunoblot. Fig. 6C (lanes 4–6) shows the
background banding pattern when the membrane was incu-
bated with anti-mouse secondary antibody (2°) alone; this illus-
trates nonspecific background bands picked up in the beads
plus lysate control lane and the IP lane (NS). However, when the
IRF-1 primary antibody was applied to the same membrane
followed by the secondary antisera, a specific IRF-1 band was
detected in the IP lane (lane 2) that corresponded to the IRF-1
band from whole cell lysate (lane 1). A duplicate membrane
showed little background from the anti-rabbit secondary anti-
body (right, top); however, when NPM (middle) or TRIM28
(bottom) antisera were used, both proteins were shown to co-
immunoprecipitate with IRF-1, and background binding in the
bead control was negligible (compare lane 2 with lane 3). In a
separate experiment (Fig. 7D), although YB-1 gave some back-
ground binding to the bead alone control (bottom; lane 3) a
significant increase in YB-1 protein was readily detected when
the IRF-1 mAb was present (lane 2), demonstrating complex
formation between these two proteins. Thus, a portion of the
endogenous IRF-1 protein can be found in complexes with
NPM, YB-1, and TRIM28.
YB-1 Can Repress IRF-1-dependent Transcription—Wewere
keen to establish whether binding of either of the novel Mf2
domain-interacting proteins, TRIM28 or YB-1, had conse-
quences in terms of IRF-1 activity. Because TRIM28 has been
reported to function as part of a multiprotein repressor com-
plex (47), we decided to concentrate on YB-1 because it is, by
itself, sufficient to modulate the activity of some transcription
factors (66, 67). Reporter assays were carried out using a range
of IRF-1-responsive gene promoters linked to luciferase. To
ensure that we measured IRF-1-dependent transcription,
H1299 cells (which have low expression of endogenous IRF-1)
were used, and the transcriptional activity of exogenous IRF-1
was determined. We also established that reporter constructs
where the IRF-1-responsive element had been mutated, or
deleted, were not stimulated by transfected IRF-1 (Fig. 7,A–D).
Interestingly, although YB-1 was able to repress IRF-1-depen-
dent transcription from all of the promoter constructs tested,
FIGURE 6. Both endogenous and exogenously expressed IRF-1 can asso-
ciate with NPM, YB-1, and TRIM28 in A375 cells. A, immunoblot (IB) of
OneStrep-IRF-1 isolated using Streptactin fromA375 cells that hadbeen tran-
siently transfected with OneStrep-IRF-1 or empty vector as indicated. The
immunoblots were probed for IRF-1 andNPM (top panels). A duplicate exper-
imentwasperformed, and immunoblotswereprobed for IRF-1 andYB-1 (bot-
tompanels). Crude cell extract (CE) and flow-through (FT) from the Streptactin
column are shown. C, a beads only control. B, immunoblot of FLAG-TRIM28
immunoprecipitated (IP) with anti-FLAG antibody fromA375 cells transiently
transfectedwithFLAG-TRIM28,OneStrep-IRF-1, or emptyvector, as indicated.
The immunoblotswereprobed for IRF-1 andFLAG.C, A375 cell lysate (4mgof
total protein/condition)was incubatedwithprotein-Gbeadsalone (Beadcon-
trol) or with protein G that had been cross-linked to anti-IRF-1 mAb (IP: mAb
IRF-1). Following extensive washing, bound proteins were analyzed by 10%
SDS-PAGE/immunoblot together with the load (Lysate). The left panels show
the membrane developed initially with anti-mouse secondary antibody (2°)
alone (middle panel); the same membrane was then probed with anti-IRF-1
followed by the anti-mouse secondary antibody to show specific IRF-1 bands
(far left panel). Right panels, the membrane was probed with anti-rabbit sec-
ondary antibody alone (top) and then sequentially with NPM polyclonal sera
and TRIM28 polyclonal sera. The data are representative of two separate
experiments. D, a separate experiment was carried out as in C and probed
with either anti-IRF-1 mAb or polyclonal YB-1 sera. NS, a nonspecific band
picked up by the secondary antibody.
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there was a significant difference in their apparent sensitivity.
Thus, YB-1 inhibited IRF-1 activity by up to 25–30% (relative to
the background; i.e. in the absence of exogenous IRF-1)when its
activity was determined using either the TLR3 (Fig. 7A) or
TRAIL (TRL3; Fig. 7C) constructs. However, IRF-1 activity
against the IFN- (Fig. 7B) and IL-7 (Fig. 7D) promoters was
reduced by as much as 60–80%. In addition, the kinetics of
YB-1-mediated repression varied, with IRF-1 activity against
the IFN- reporter showing significant inhibition at the lowest
amount of YB-1 used (50 ng), whereas effects on IRF-1 activity
assayed using the other reporters required higher amounts of
YB-1 (200–400 ng). In all cases, no effect of YB-1was seen on the
activity of promoters that did not contain a functional IRF-1
response element. The data presented in Fig. 7 suggest that bind-
ing of YB-1 to theMf2 domain of IRF-1 can be exploited to mod-
ulate the function of IRF-1 as a regulator of gene expression.
FIGURE 7. YB-1 represses IRF-1-dependent gene activation. A, H1299 cells were co-transfectedwith a TLR3-Luc reporter plasmid (WT ormutant lacking the
ISRE; 140ng), a controlRenilla-Lucplasmid (60ng), pcDNA3-IRF-1 (100ng), and a titrationofMyc-YB-1 (0–400ng), as indicated.DNAamountswerenormalized
across samplesusingpcDNA3emptyvector. Post-transfection (24h), the cellswereharvested, anddual luciferase reporter assayswereperformed. Resultswere
normalized by expressing firefly luciferase/Renilla luciferase activity in relative light units (RLU) as themean S.D. (error bars). YB-1, IRF-1, andGAPDH (loading
control) protein levels were detected by SDS-PAGE/immunoblot. B–D, as in A except that a reporter plasmid containing firefly luciferase regulated by the IFN
promoter (WT ormutant lacking the ISRE; B) or the TRAIL promoter (TRL3WT ormutantwithout the ISRE; C) or the IL-7 promoter (WT ormutantminus the ISRE;
D) were used instead of the TLR3 reporter construct.
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DISCUSSION
It is now well accepted that ID proteins or domains are highly
represented in the eukaryotic proteome and are particularly prev-
alent in the proteins involved in cell signaling and the control of
gene transcription (1, 48, 49). Thus, more than half of all eukary-
otic proteins have unstructured domains, whereas it is estimated
that 25–30%of proteins can be found in amostly disordered state.
The challenge for experimentalists is therefore to design
approaches to validate ID domains and define their functions in
the absence of conventional structural data. Because it is vital to
identify the interactome of a protein or domain in order to under-
stand its role in any cellular process, defining ID-binding factors
for a given protein or protein domain must be a priority. Here we
used IRF-1-based aptamers to askwhether theMf2 interface from
themajor intrinsicallydisordereddomainof IRF-1wasamultipro-
tein binding site for regulators of IRF-1 function.
Exogenous IRF-1 is expressed at low levels in cells, making it
difficult to use conventional approaches, such as TAP-tagging
linked tomass spectrometry, to identify regulators. In fact, we can
find no reports of these approaches being applied successfully to
the identification of IRF-1-interacting proteins. On the other
hand, full-length immobilizedHis- orGST-tagged IRF-1 has been
usedasanaffinitymatrix to identify interactingproteins frommet-
abolically labeledK-562cells (25) or fromJurkatTcells (50).These
studies identified NPM (25) and CKII (50), respectively, as IRF-1-
interacting factors and potentially relevant physiological regula-
tors. In the current study, we used peptide aptamers based on the
sequence of IRF-1 to generate affinity matrices because we rea-
soned that this approach would favor the identification of (i) rela-
tively low affinity interactions as high concentration of the “bait”
peptide could be achieved and (ii) short linear interaction motifs
prevalent in ID domains. In addition to extending our knowledge
about the interactions between NPM (25) and CKII (50) with
IRF-1 by defining them as Mf2 domain-binding proteins, we also
identified a number of other potential IRF-1-interacting proteins
(supplemental Table T1). A portion of the proteins identified as
binding to the Mf2 domain are known to be involved in protein
synthesis and more precisely are ribosome-associated proteins;
however, many of these factors have previously been identified as
components of the NPM interactome (51–54) andmay therefore
bind IRF-1 indirectly. We therefore narrowed down our proteins
of interest by leaving out those that fell into the category of protein
synthesis when analyzed byDAVID (Fig. 2C). Instead, we focused
on proteins with a link to transcriptional regulation that have also
been implicated in cancer.
Although,asnotedabove,NPMhadpreviouslybeenidentifiedasa
potential regulatorof IRF-1-mediatedgeneexpression (25), the inter-
action between these two proteins has not been characterized in
detail.HereweshowthatNPMbindsdirectlytoIRF-1throughashort
linear motif in the Mf2 domain where amino acids 133–140 are
required for efficient binding and are sufficient to forma stable inter-
action, competing for bindingwith full-length IRF-1 toNPM(Figs. 3
and 4). Interestingly, the NPM binding motif lies within the nuclear
localizationsequence(NLS)ofIRF-1(aminoacids116–139)(55),and
previous studies have demonstrated binding of NPM to the NLS of
several viral proteins, including SV40 T-antigen (56, 57). Classical
NLS sequences are characterized by clusters of basic residues and
thereforefitwell intothecontextofIDdomainsthatarefavoredbythe
presence of polar hydrophilic amino acids (58, 59). The location of
NLS motifs within inherently flexible ID regions is advantageous
because itallowsmodificationof local structures inresponsetodiffer-
ent binding proteins and facilitates competitive binding to multiple
targets. For example, the disorderedNLS inNF-B is exposedwhen
theprotein is both free and in theDNAbound state, and this appears
to facilitate its interaction with either importin- ormembers of the
IB family that can inhibit its nuclear import (59). Thus, some of the
proteins that bind to the Mf2 domain of IRF-1 may be expected to
regulateitsnuclearimport.Indeed,NPMhasbeenshowntostimulate
nuclear import of someof its client proteins (57, 60).
Of the other proteins identified in the IRF-1 aptamer screen, we
chose to concentrate on two transcriptional regulators YB-1 and
TRIM28 based on their link to cancer development (46, 61–64).
TRIM28 has been shown to function, as part of amultiprotein com-
plex, to repress gene expression (47, 65). YB-1 can interact with vari-
ous transcription factors to either repress or activate gene expression
(66, 67). In thecurrent study,we found thatYB-1could repress IRF-1
transcriptional activity as determined using reporter assays. Interest-
ingly,unlikeNPM,whichappears torepress IRF-1activity toasimilar
extentindependentofthetargetpromoter(25), therewasasignificant
differenceintheefficacyofYB-1asaninhibitorofIRF-1dependenton
the reporter construct used. It will therefore be of interest to deter-





ate by “discovering” novel binding proteins. The use of mass spec-
trometry to identify “stable” proteinprotein complexeshasproved to
be a paradigm-shifting tool. Indeed, this approach has expanded our
view of the scope and diversity of an interactome for a given protein.
Forexample,284proteinshavebeenidentifiedinanERKinteractome
screen (70), and292proteinshavebeen identifiedasbindingpartners
for 14-3-3 (71). We report here on the use of peptide aptamers to
identify a multiprotein binding interface for a range of cellular pro-
teins that can bind to the tumor suppressor protein IRF-1. This has
highlighted a potential role for theMf2 domain in the negative regu-
lation of IRF-1 transcription by known transcriptional regulators like
NPM(25),YB-1(67),andTRIM28(64,65).Thus, inadditiontolaying
the foundations for further studies to characterize the physiological
role of YB-1 and TRIM28 as regulators of IRF-1 function, this study
suggests that theMf2 interactome will be modulated in response to
IRF-1-activatingsignals.Wewill thereforeconsiderexpandingonthis
approach to define the dynamicMf2domain interactome.
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